Welcome to our dedicated page for Curaleaf Hldgs news (Ticker: CURLF), a resource for investors and traders seeking the latest updates and insights on Curaleaf Hldgs stock.
Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Summary not available.
Curaleaf Holdings announces participation in key investor conferences in January 2023. CEO Matt Darin will engage in fireside chats at the ICR Conference on January 10 and the Needham Growth Conference on January 12, as well as a panel discussion at the ATB Capital Markets' Institutional Investor Conference on the same day. Curaleaf continues to expand its presence in the cannabis market, operating 145 dispensaries across 21 states in the U.S. and being a leading player in Europe. For more details, visit their investor relations site.
Summary not available.
Curaleaf Holdings (CURLF) has announced the appointment of Michelle Bodner and Shasheen Shah to its Board of Directors, effective December 31, 2022. Bodner brings extensive experience in operations and executive coaching, having previously served in various roles within Curaleaf. Shah, a leadership development coach, will also add strategic insights to the board. With these additions, the board now has eight members, including four independent directors. This move aims to enhance governance as Curaleaf prepares for its 2023 initiatives.
Curaleaf Holdings announced a groundbreaking partnership between its Grassroots brand and Ganjier, launching a unique cannabis education program. This initiative aims to elevate the cannabis industry's standards through training for 100 nominated team members and external partners. The program incorporates a comprehensive online curriculum, culminating in an in-person training session in Humboldt, California. The Grassroots brand is operational in seven states and focuses on high-quality cannabis products, aligning with Curaleaf's commitment to cannabis education and professionalism.
Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) has announced its participation in investor conferences in December 2022. CEO Matt Darin will engage in a fireside chat at Cowen's 5th Annual Cannabis Conference on December 6, followed by a lunch panel at Stifel Canada's 3rd Annual Future of Healthcare Conference on December 7. Curaleaf is recognized as a leader in the cannabis sector, operating 144 dispensaries across 21 states and being the largest vertically integrated cannabis company in Europe. For more details, visit Curaleaf's Investor Relations website.
Summary not available.
Curaleaf Holdings reported Q3 2022 revenue of $340 million, marking a 1% sequential increase and 7% year-over-year growth. The company achieved Adjusted EBITDA of $84 million, up 18% YoY, with a 24.7% margin. Despite a net loss of $51 million, improved cash flow of $60 million was generated. The company expanded its retail footprint to 137 locations and increased retail revenue by 16%. Recent acquisitions, including Four20 Pharma and Tryke, aim to strengthen market position.
Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) has announced its participation in several investor conferences in November 2022. The events include MJBizCon from November 15-18, where Curaleaf management will host investor meetings, and the CannaVest West Institutional Capital Forum from November 16-17, featuring keynote speeches by Executive Chairman Boris Jordan and CEO Matt Darin. Curaleaf operates in 21 states with 142 dispensaries and is recognized as a leader in the cannabis industry, focusing on consumer products and market expansion.
Curaleaf International announces significant findings from a clinical study on cannabidiol (CBD) treatment for Vestibulodynia (VBD), presented by Chief Scientific Officer Dr. Barbara Pacchetti at a medical cannabis conference on October 21-22, 2022. The study, involving 60 patients, demonstrated improved pain outcomes and muscular tone. Additionally, preclinical studies pointed to CBD's potential in treating psychiatric disorders and migraine pain. Curaleaf focuses on advancing scientific understanding of medical cannabis in collaboration with top academic institutions.